NCT03541980

Brief Summary

The purpose of this study is to determine whether IV acetaminophen can decrease the need for subsequent opioid administration in the acute management of sickle cell crisis pain in the pediatric emergency room.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
71

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 20, 2018

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 17, 2018

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 31, 2018

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2020

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

April 2, 2021

Completed
Last Updated

April 2, 2021

Status Verified

March 1, 2021

Enrollment Period

2 years

First QC Date

May 17, 2018

Results QC Date

October 15, 2020

Last Update Submit

March 8, 2021

Conditions

Keywords

sickle cellacetaminophen in pain crisesopioid-sparing

Outcome Measures

Primary Outcomes (1)

  • Cumulative Opioid Dosing

    Total dosing of opioid given after initial evaluation in mg/kg

    120 minutes

Secondary Outcomes (4)

  • Pain Scores

    at disposition

  • Inpatient Admission

    120 minutes

  • Adverse Effects

    120 minutes

  • Percentage of the Patients Reporting Satisfaction

    120 minutes

Study Arms (2)

Intervention

ACTIVE COMPARATOR

Patients allocated to receive IV acetaminophen

Drug: Acetaminophen

Placebo

PLACEBO COMPARATOR

Patients allocated to receive IV normal saline placebo

Drug: Normal saline

Interventions

Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen

Also known as: Ofirmev, Tylenol
Intervention

Normal saline volume equivalent

Also known as: Sodium chloride solution
Placebo

Eligibility Criteria

Age4 Years - 16 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Any patient age 4-16 years with sickle cell disease who presents the Pediatric ER with acute sickle cell pain crisis with a pain of 6/10 or higher

You may not qualify if:

  • Patient with fever (38C or 100.4F)
  • Patient less than age 4 years
  • Patient greater than age 16 years
  • Patient with hypersensitivity/allergy to either morphine, NSAIDs, or acetaminophen
  • Patient received acetaminophen within the past 4 hours
  • Patient with known liver disease or renal disease
  • Patient not requiring IV morphine (pain score 5/10 or less)
  • Patient enrolled in the study within the past 72 hours

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Newark Beth Israel

Newark, New York, 07112, United States

Location

Related Publications (1)

  • Dhebaria T, Sivitz A, Tejani C. Does Intravenous Acetaminophen Reduce Opioid Requirement in Pediatric Emergency Department Patients With Acute Sickle Cell Crises? Acad Emerg Med. 2021 Jun;28(6):639-646. doi: 10.1111/acem.14149. Epub 2020 Oct 30.

MeSH Terms

Conditions

Vaso-Occlusive Crises

Interventions

AcetaminophenSaline SolutionSodium Chloride

Condition Hierarchy (Ancestors)

Anemia, Sickle CellAnemia, Hemolytic, CongenitalAnemia, HemolyticAnemiaHematologic DiseasesHemic and Lymphatic DiseasesHemoglobinopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical PreparationsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Results Point of Contact

Title
Dr Cena Tejani
Organization
Newark Beth Israel Medical Center

Study Officials

  • Cena Tejani, MD

    Children's Hospital of NJ at Newark Beth Israel Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 17, 2018

First Posted

May 31, 2018

Study Start

February 20, 2018

Primary Completion

February 20, 2020

Study Completion

February 20, 2020

Last Updated

April 2, 2021

Results First Posted

April 2, 2021

Record last verified: 2021-03

Locations